# US 2024/0200048 A1 · Peptide translated by circular rna circ-ace2 and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200048 A1
- Document ID: US20240200048A1
- Status: Published application
- Kind: A1
- Application number: 18/525,885
- Filed: 2023-12-01
- Published: 2024-06-20
- Earliest claimed: 2021-06-04
- Assignees: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
- Applicants: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
- Inventors: Xingguo LIU; Ming LIU; Maolei ZHANG; Guangsuo XING; Shan LIANG
- Web page: https://patentgrep.com/patent/US20240200048A1

## CPC

- C12N 9/485: {Exopeptidases (3.4.11-3.4.19)}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61P 31/14: for RNA viruses
- C12N 15/85: for animal cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/02: containing a signal sequence
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2800/107: for mammalian
- C12Y 304/17023: Angiotensin-converting enzyme 2 (3.4.17.23)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Provided are a polypeptide translated by a circular RNA Circ-ACE2 and an application thereof, the circular RNA molecule comprising at least one of the following sequences: 1) an RNA sequence as set forth in SEQ ID NO: 1; 2) an RNA sequence having at least 70% identity with 1), preferably an RNA sequence having at least 80% identity with 1), preferably an RNA sequences having at least 85% identity with 1), preferably an RNA sequence having at least 90% identity with 1), preferably an RNA sequence having at least 95% identity with 1), and more preferably, an RNA sequence having at least 99% identity with 1).

## Claims

### Claim 1

An isolated circular RNA molecule, wherein the circular RNA molecule comprises at least one of the following sequences:
1) an RNA sequence as set forth in SEQ ID NO: 1;
2) an RNA sequence having at least 70% identity with 1).

### Claim 2 (depends on 1)

The isolated circular RNA molecule according to claim 1, wherein the circular RNA molecule comprises at least one of the following sequences:
1) an RNA sequence as set forth in SEQ ID NO: 1;
2) an RNA sequence having at least 80% identity with 1), preferably an RNA sequence having at least 85% identity with 1), preferably an RNA sequence having at least 90% identity with 1), preferably an RNA sequence having at least 95% identity with 1), and more preferably, an RNA sequence having at least 99% identity with 1).

### Claim 3 (depends on 1)

The circular RNA molecule according to claim 1, wherein the circular RNA molecule is formed by a separate cyclization of a second exon of an mRNA sequence encoding angiotensin-converting enzyme 2;
optionally, the cyclization occurs in placental tissues.

### Claim 4 (depends on 1)

The circular RNA molecule according to claim 1, wherein the circular RNA molecule is formed by linking a starting nucleotide and a terminal nucleotide of the nucleotide sequence as set forth in 1) or 2), the starting nucleotide being set as a first nucleotide of the circular RNA molecule.

### Claim 5 (depends on 4)

The circular RNA molecule according to claim 4, wherein a coding region of the circular RNA molecule comprises nucleotides at position 104 to position 45 of the circular RNA molecule.

### Claim 6 (depends on 5)

The circular RNA molecule according to claim 5, a nucleic acid sequence of the coding region of the circular RNA comprises at least one of the following sequences:
1) an RNA sequence as set forth in SEQ ID NO: 2;
2) an RNA sequence having at least 70% identity with 1), preferably an RNA sequence having at least 80% identity with 1), preferably an RNA sequence having at least 85% identity with 1), preferably an RNA sequence having at least 90% identity with 1), preferably an RNA sequence having at least 95% identity with 1), and more preferably, an RNA sequence having at least 99% identity with 1).

### Claim 7

A polypeptide, wherein an amino acid sequence of the polypeptide comprises at least one of the following sequences:
1) an amino acid sequence as set forth in SEQ ID NO: 3;
2) an amino acid sequence having at least 70% identity with 1).

### Claim 8 (depends on 7)

The polypeptide according to claim 7, wherein an amino acid sequence of the polypeptide comprises at least one of the following sequences:
1) an amino acid sequence as set forth in SEQ ID NO: 3;
2) an amino acid sequence having at least 80% identity with 1), preferably an amino acid sequence having at least 85% identity with 1), preferably an amino acid sequence having at least 90% identity with 1), preferably an amino acid sequence having at least 95% identity with 1), and more preferably, an amino acid sequence having at least 99% identity with 1).

### Claim 9 (depends on 7)

The polypeptide according to claim 7, wherein the polypeptide comprises a signal peptide sequence;
optionally, an amino acid sequence of the signal peptide is MSSSSWLLLSLVAVTAA.

### Claim 10 (depends on 7)

The polypeptide according to claim 7, wherein the peptide is present in placental tissues.

### Claim 11 (depends on 7)

A fusion protein, comprising the polypeptide according to claim 7 and an Fc, wherein a C-terminal of the polypeptide is linked to an N-terminal of the Fc.

### Claim 12 (depends on 11)

The fusion protein according to claim 11, wherein the fusion protein comprises at least one of the following sequences:
1) an amino acid sequence as set forth in SEQ ID NO: 4;
2) an amino acid sequence having at least 70% identity with 1).

### Claim 13 (depends on 11)

The fusion protein according to claim 11, wherein the fusion protein comprises at least one of the following sequences:
1) an amino acid sequence as set forth in SEQ ID NO: 4;
2) an amino acid sequence having at least 80% identity with 1), preferably an amino acid sequence having at least 85% identity with 1), preferably an amino acid sequence having at least 90% identity with 1), preferably an amino acid sequence having at least 95% identity with 1), and more preferably, an amino acid sequence having at least 99% identity with 1).

### Claim 14 (depends on 11)

An isolated nucleic acid encoding the fusion protein according to claim 11.

### Claim 15 (depends on 14)

The nucleic acid according to claim 14, wherein the nucleic acid encoding the fusion protein comprises at least one of the following sequences:
1) a nucleotide sequence as set forth in SEQ ID NO: 5;
2) a nucleotide sequence having at least 70% identity with 1).

### Claim 16 (depends on 15)

The nucleic acid according to claim 15, wherein the nucleic acid encoding the fusion protein comprises at least one of the following sequences:
1) a nucleotide sequence as set forth in SEQ ID NO: 5;
2) a nucleotide sequence having at least 80% identity with 1), preferably a nucleotide sequence having at least 85% identity with 1), preferably a nucleotide sequence having at least 90% identity with 1), preferably a nucleotide sequence having at least 95% identity with 1), and more preferably, a nucleotide sequence having at least 99% identity with 1).

### Claim 17 (depends on 7)

A method for inhibiting the infection of cells by COVID-19, comprising:
contacting the COVID-19 or cells to be infected with the polypeptide according to claim 7.

### Claim 18 (depends on 7, 17)

The method according to claim 17, wherein the contacting is carried out by the following steps:
1) performing a first mixing treatment of the COVID-19 with the polypeptide according to claim 7;
2) performing a second mixing treatment of the mixture obtained in step 1) with the cells to be infected to inhibit the infection of the cells by the COVID-19.

### Claim 19 (depends on 17)

The method according to claim 17, wherein a final concentration of the polypeptide in a mixed system is 10 μg/mL or 160 μg/mL.

### Claim 20 (depends on 7)

A method for treating or preventing novel coronavirus pneumonia, comprising administering to a patient the pharmaceutically acceptable polypeptide according to claim 7.
